Search results
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a...
WPRI Providence· 3 days agoTyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been ...
Gene Panel Predicts Early HER2+ Breast Cancer Prognosis
Medscape· 7 days agoPatients with early-stage HER2+ breast cancer could soon be offered less intensive treatment based...
Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024
KTLA-TV Los Angeles· 2 days agoShanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers ...
Scientists uncover new treatment pathway for rare 'spider web' childhood brain tumors
Medical Xpress· 2 days agoRather than a solid tumor, gliomatosis cerebri typically presents as a spider's web of cancer...
Overcoming Resistance and Toxicity Hurdles: PST's Localized Drug Delivery Technology May Unlock...
FOX 23 News Albany· 4 days agoPostsurgical Therapeutics, Inc. (PST) today announced the successful completion of an in vivo study of its proprietary injectable gel formulation containing two drugs used to treat several types ...
Ipilimumab, a Pioneer Breakthrough in Cancer Treatment
Forbes· 7 days agoIn 2011, the first in a new generation of anticancer drugs called checkpoint inhibitors was...
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
FOX 23 News Albany· 5 days agoNovel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Anixa Biosciences.
Nimbus reports positive data from Phase I/II solid tumour therapy trial
Clinical Trials Arena via Yahoo Finance· 3 days agoThe latest findings as of 18 March included data from 44 subjects in the dose...) achieved a...
ASCO: With hopes high, Regeneron misses mark with just 1 complete response in solid tumor trial so...
FierceBiotech· 3 days agoRegeneron’s costimulatory bispecific antibody REGN7075 is being tested in patients with advanced ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 3 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific antibody, REGN7075 ...